IsoRay Inc

Type: Company
Name: IsoRay Inc
First reported Oct 08 2014 - Updated Oct 08 2014 - 1 reports

ZELTIQ Announces Conference Call and Webcast of Third Quarter 2014 Financial Results to Be Held on O...

BioMedReports Healthcare Review: IsoRay, CombiMatrix, Lakeland Industries, Tenet Healthcare, Pluristem Therapeutics: U.S. s... http://t.co/dtod3cqYdn ... [Published BioMedReports - Oct 08 2014]
First reported Oct 07 2014 - Updated Oct 08 2014 - 1 reports

Morning Market Movers

IsoRay (NYSE: ISR) shares jumped 44.93% to $2.00 after the company announced early success for young Peruvian girl utilizing Cesium-131 in first stereotactic implant for inoperable brain cancer.IFM Investments (NYSE: CTC) rose 24.28% to $1.74 after the ... [Published Benzinga.com - Oct 07 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Market Wrap: SodaStream Slammed on Sales Miss; Herbalife Confident in FTC Probe Results; Cliffs Natural Now Junk at S

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=9894096 for the full story.Related Stocks:Amazon.com Inc BRISTOL-MYERS SQUIBB CO. CHRISTOPHER AND BANKS CORP. CLIFFS NATURAL RESOURCES, Inc. COTY, Inc. FIREEYE FIRST TRUST CHINA ... [Published Nation's Restaurant News - Oct 07 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 6 reports

IsoRay (ISR) Succesful Results After Cesium-131 Seed Implant Into Brain Tumor

(live-PR.com) - Keep a close eye on IsoRay, Inc. (ISR). The company reported positive results of its Cesium-131 seed in a young female patient with an inoperable glioblastoma brain tumor. The 2.7 cm tumor was located very close to the brainstem, making ... [Published Live-PR.com - Oct 07 2014]
First reported Sep 30 2014 - Updated Oct 01 2014 - 1 reports

IsoRay, Inc. Reports Fiscal Year 2014 Results

Reports Growing List of Major Accomplishments ... [Published Marketwire - Breaking News Releases - Sep 30 2014]
Entities: IsoRay Inc, Fiscal Year
First reported Sep 30 2014 - Updated Oct 01 2014 - 1 reports

IsoRay Annual Loss Widens - Quick Facts

IsoRay, Inc. (ISR: Quote) Tuesday reported fiscal 2014 net loss applicable to shareholders of $6.7 million or $0.16 per share, wider than $3.87 million or $0.11 per share in the prior year.Product sales declined to $4.22 million from $4.53 million a year ... [Published RTTNews.com - Sep 30 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Sector Update: Health Care Stocks Drifting Lower Near Close; IsoRay Zapped After FY14 Results Come Up Short

PFE -0.30%ABT -0.31%MRK +0.46%AMGN +0.44%Health care stocks were set to close in the red Tuesday with the NYSE Health Care Sector Index declining about 0.4% and shares of health care companies in the S&P 500 off 0.3% as a group.In company news, IsoRay ... [Published Nasdaq - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 1 reports

ISORAY, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Critical Accounting Policies and Estimates Management's discussion and analysis of the Company's financial condition and results of operations is based upon its consolidated financial statements, which have been prepared in accordance with accounting ... [Published Town Hall - Sep 29 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Oracle Corporation : Stocks Creating Buzz Today

Deerfield Beach, FL / Sept 19, 2014 / The Federal Reserve?s monetary policy meeting was the talking point at the start of this week. All eyes were on Fed?s monetary policy statement, which was released on Wednesday. The Fed surprised the market by maintaining ... [Published 4 Traders - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

IsoRay Has Tremendous Potential Gaining More Published Peer Reviews

/ A report from BCC Research titled "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" notes that the worldwide market for the prevention and treatment of cancer was valued at $26.1 billion in 2011 and is expected to cross ... [Published 4 Traders - Sep 18 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

IsoRay's Cesium-131 Cancer Treatment Products and Methods to Be Featured in Oral Presentations by Industry Leaders During the American Society for Radiation Oncology Convention (ASTRO)

Topics Include Use of Cesium-131 for GYN Malignancies, Focal Prostate Brachytherapy and Prostate "Real Time" Stranded Seed Technique ... [Published Marketwire - Breaking News Releases - Sep 09 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay

LONDON, September 3, 2014 /PRNewswire/ --The US markets on Tuesday, September 02, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 17,067.56, down 0.18% and the NASDAQ Composite closed at 4,598.19, up 0.39%. The S&P 500 finished ... [Published PR Newswire: Financial Services - Sep 03 2014]

Quotes

IsoRay Chairman and CEO Dwight Babcock commented, "We can only hope we have positively impacted this child's life. IsoRay is committed to supporting many of these difficult and recurrent cancer cases giving growing evidence of Cesium-131 cancer killing ability. This new stereotactic approach of placing Cesium-131 seeds in aggressive tumors will offer more hope when inoperable cancers are discovered throughout the body. Our hope is that with time, a growing number of leading surgeons and radiation oncologists will see the significant results being achieved by major medical institutions currently utilizing Cesium -131 and adopt it for their patients."
"The study results are important and highlight the effectiveness of Cesium-131. These studies are part of IsoRay's strategy as Babcock told us. The company's goal is to get as many peer reviews done from different institutions in order to create awareness about Cesium-131" he added
"We rate ISORAY INC (ISR) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and feeble growth in its earnings per share."
Original Article: NEXT ARTICLE More From BioPortfolio on "IsoRay announces Cesitrex treatment for metastatic brain cancer using Gliasite radiation therapy balloon catheter system"

More Content

All (40) | News (23) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Pre-market Biotech Picks - Gilead Sciences, Man... [Published Financial Services - Oct 14 2014]
ZELTIQ Announces Conference Call and Webcast of... [Published BioMedReports - Oct 08 2014]
Market Wrap: SodaStream Slammed on Sales Miss; ... [Published Nation's Restaurant News - Oct 07 2014]
IsoRay (ISR) Succesful Results After Cesium-131... [Published Live-PR.com - Oct 07 2014]
IsoRay, Inc. Reports Success In Brain Cancer Tr... [Published Benzinga.com - Oct 07 2014]
Why IsoRay (ISR) Stock Is Surging Today [Published The Street Latest - Oct 07 2014]
Morning Market Movers [Published Benzinga.com - Oct 07 2014]
ETF Preview: ETFs, Futures Weaker Ahead of Augu... [Published Nasdaq - Oct 07 2014]
Isoray Announces Early Success for Young Peruvi... [Published Stock Nod - Oct 07 2014]
Isoray Announces Early Success for Young Peruvi... [Published Marketwire - Breaking News Releases - Oct 07 2014]
Isoray : Announces Early Success for Young Peru... [Published 4 Traders - Oct 07 2014]
Sector Update: Health Care Stocks Drifting Lowe... [Published Nasdaq - Sep 30 2014]
IsoRay Annual Loss Widens - Quick Facts [Published RTTNews.com - Sep 30 2014]
IsoRay, Inc. Reports Fiscal Year 2014 Results [Published Marketwire - Breaking News Releases - Sep 30 2014]
ISORAY, INC. - 10-K - MANAGEMENT'S DISCUSSION A... [Published Town Hall - Sep 29 2014]
Oracle Corporation : Stocks Creating Buzz Today [Published 4 Traders - Sep 19 2014]
IsoRay Has Tremendous Potential Gaining More Pu... [Published 4 Traders - Sep 18 2014]
IsoRay's Cesium-131 Cancer Treatment Products a... [Published Marketwire - Breaking News Releases - Sep 09 2014]
Technical Coverage on Biotech Equities - Galena... [Published PR Newswire: Financial Services - Sep 03 2014]
Top Swing Trade Ideas for Thursday, Aug. 21: Al... [Published The Street Latest - Aug 21 2014]
IsoRay's Cesium-131 Isotope Produces Excellent ... [Published Marketwire - Breaking News Releases - Aug 05 2014]
Market Momentum on Biotech Stocks -- IsoRay, Ne... [Published Financial Services - Jul 31 2014]
Why IsoRay (ISR) Stock Is Spiking Today [Published The Street Latest - Jul 14 2014]
IsoRay Makes First Cesium-131 Delivery for Trea... [Published Marketwire - Breaking News Releases - Jul 14 2014]
IsoRay Announces Its Addition to the Russell Mi... [Published Marketwire - Breaking News Releases - Jun 30 2014]
IsoRay announces Cesitrex treatment for metasta... [Published BioPortfolio - Jun 25 2014]
A Beaten-Down Biotech Stock Gearing Up for a Bi... [Published The Street Latest - Jun 24 2014]
Why IsoRay (ISR) Stock Is Surging Today [Published The Street Latest - Jun 24 2014]
IsoRay Announces World's First Liquid Cesium-13... [Published Marketwire - Breaking News Releases - Jun 24 2014]
Health Care Sector Stocks Technical Analysis --... [Published Financial Services - Jun 23 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Isoray Announces Early Success for Young Peruvi... [Published Marketwire - Breaking News Releases - Oct 07 2014]
7-Year-Old Currently Back in School With No Restrictions and Normal Activities ...
IsoRay, Inc. Reports Fiscal Year 2014 Results [Published Marketwire - Breaking News Releases - Sep 30 2014]
Reports Growing List of Major Accomplishments ...
IsoRay's Cesium-131 Cancer Treatment Products a... [Published Marketwire - Breaking News Releases - Sep 09 2014]
Topics Include Use of Cesium-131 for GYN Malignancies, Focal Prostate Brachytherapy and Prostate "Real Time" Stranded Seed Technique ...
Technical Coverage on Biotech Equities - Galena... [Published PR Newswire: Financial Services - Sep 03 2014]
LONDON, September 3, 2014 /PRNewswire/ --The US markets on Tuesday, September 02, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 17,067.56, down 0.18% and the NASDAQ Composite closed at 4,598.19, up 0.39%. The S&P 500 finished ...
IsoRay's Cesium-131 Isotope Produces Excellent ... [Published Marketwire - Breaking News Releases - Aug 05 2014]
100% Local (Resection Cavity) Freedom From Progression With 19.3 Month Median Follow-Up ...
1 2 3

Press Releases

sort by: Date | Relevance
Pre-market Biotech Picks - Gilead Sciences, Man... [Published Financial Services - Oct 14 2014]
Market Momentum on Biotech Stocks -- IsoRay, Ne... [Published Financial Services - Jul 31 2014]
Health Care Sector Stocks Technical Analysis --... [Published Financial Services - Jun 23 2014]
Health Care Stocks on our Scanner -- Research o... [Published Financial Services - May 01 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.